



Contact:

Dr. Misha Plam
President and CEO

T: (303) 641-3669

misha.plam@amidebio.com

www.amidebio.com

*AmideBio CTO Dr. Michael Stowell's to present a poster at 76 American Diabetes Association (ADA)
in New Orleans on June 11, 2016*

BOULDER, CO, June 10, 2016 – AmideBio, LLC, a privately held biopharmaceutical company, announced that AmideBio's CTO, Dr. Michael H. B. Stowell is going to present a poster titled "*SPARSE MATRIX SAMPLING OF ANTI-FIBRILLATION SEQUENCE MUTATIONS YIELDS A LIBRARY OF NOVEL SOLUTION STABLE GLUCAGON ANALOGS SUITABLE FOR AN ARTIFICIAL PANCREAS*".

"The poster presentation describes the culmination of one of AmideBio's discovery programs in the diabetes field and exemplifies the companies transition from early stage discovery to advanced drug targets ready for clinical trials. The novel glucagons developed under this program represent an important step in the quest for an artificial pancreas" said Dr. Misha Plam, AmideBio's President and CEO.

About AmideBio:

AmideBio, based in Boulder, CO, is a biotechnology company leveraging its proprietary BioPure™ platform technology to deliver difficult-to-manufacture peptides to researchers and the industry, while also building a pipeline of novel biotherapeutics. AmideBio's proprietary technology enables the rapid and economical manufacture of pure peptides of any length. This innovative technology combines recombinant and chemical methods, eliminates many of the inefficient and costly steps of processes that rely only on one or the other approach and, results in fewer batch inconsistencies and less waste generation. These advantages enable AmideBio to offer its cost-efficient technology and peptide product candidates to the pharmaceutical and biotech industry. The Company continues to expand its proprietary technology platform in the areas of protein production, biosimilar therapeutic manufacturing and internal research and development of novel biotherapeutics aimed at metabolic, inflammatory and neurodegenerative diseases.

About American Diabetes Association:

The American Diabetes Association's Scientific Sessions offers researchers and health care professionals from around the world the unique opportunity to share ideas and learn about the significant advances in diabetes research, treatment, and care.

Over the course of five days, participants will receive exclusive access to more than 2,500 original research presentations, take part in provocative and engaging exchanges with leading diabetes experts, and expand their professional networks.

The program will begin on Friday, June 10 at 11:45 a.m. with our new Mini-Symposia sessions and conclude on Tuesday, June 14 at 12:15 p.m. following the ADA Presidents Oral Session.

- ENDS -